Dr Christopher Guise

Biography

Research interests:

Selected publications and creative works (Research Outputs)

  • Li, X., Guise, C. P., Taghipouran, R., Yosaatmadja, Y., Ashoorzadeh, A., Paik, W.-K., ... Xu, Y. (2017). 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. European journal of medicinal chemistry, 135, 531-543. 10.1016/j.ejmech.2017.04.049
    Other University of Auckland co-authors: Christopher Squire, Adam Patterson, Jeffrey Smaill, Amir Ashoorzadeh
  • Zygouropoulou, M., Kubiak, A. M., Copp, J. N., Dubois, L. J., Mowday, A. M., Guise, C. P., ... Patterson, A. V. (2017). Clostridium as "Trojan Horse" Vectors for Cancer Treatment. Paper presented at 20th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, DC. 10 May - 13 May 2017. MOLECULAR THERAPY. (pp. 1).
    Other University of Auckland co-authors: Jeffrey Smaill, Adam Patterson
  • Mowday, A. M., Guise, C. P., Kubiak, A. M., Minton, N. P., Abbattista, M. R., Lambin, P., ... Patterson, A. V. (2017). Efficacy of a Novel Enzyme/Prodrug Combination for Clostridia Directed Enzyme Prodrug Therapy. Paper presented at 20th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, DC. 10 May - 13 May 2017. MOLECULAR THERAPY. (pp. 2).
    Other University of Auckland co-authors: Jeffrey Smaill, Adam Patterson
  • Mo, C., Zhang, Z., Guise, C. P., Li, X., Luo, J., Tu, Z., ... Ren, X. (2017). 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS medicinal chemistry letters, 8 (5), 543-548. 10.1021/acsmedchemlett.7b00091
    Other University of Auckland co-authors: Adam Patterson, Jeffrey Smaill
  • Copp, J. N., Mowday, A. M., Williams, E. M., Guise, C. P., Ashoorzadeh, A., Sharrock, A. V., ... Ackerley, D. F. (2017). Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy. Cell chemical biology, 24 (3), 391-403. 10.1016/j.chembiol.2017.02.005
    Other University of Auckland co-authors: Jeffrey Smaill, Amir Ashoorzadeh, Jack Flanagan, Adam Patterson, Alexandra Mowday
  • Mowday, A. M., Ashoorzadeh, A., Williams, E. M., Copp, J. N., Silva, S., Bull, M. R., ... Guise, C. P. (2016). Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy. Biochemical pharmacology, 116, 176-187. 10.1016/j.bcp.2016.07.015
    URL: http://hdl.handle.net/2292/30209
    Other University of Auckland co-authors: Alexandra Mowday, Jack Flanagan, Adam Patterson, Bob Anderson, Jeffrey Smaill, Maria Abbattista, Amir Ashoorzadeh, Matthew Bull
  • Mowday, A. M., Guise, C. P., Ackerley, D. F., Minton, N. P., Lambin, P., Dubois, L. J., ... Patterson, A. V. (2016). Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress. Cancers, 8 (7).10.3390/cancers8070063
    URL: http://hdl.handle.net/2292/30203
    Other University of Auckland co-authors: Adam Patterson, Jeffrey Smaill, Alexandra Mowday
  • Silva, S., Jackson, V., Guise, C., Abbattista, M., Bull, M., Grey, A. C., ... Pearce, T. (2015). Preclinical Efficacy of Tarloxotinib Bromide (TH-4000), a Hypoxia-Activated EGFR/HER2 Inhibitor: Rationale for Clinical Evaluation in EGFR Mutant, T790M-Negative NSCLC Following Progression on EGFR-TKI Therapy. Paper presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts. 5 November - 9 November 2015.
    Other University of Auckland co-authors: Angus Grey, Maria Abbattista, Bob Anderson, Amir Ashoorzadeh, Adam Patterson, Jeffrey Smaill, Matthew Bull, Victoria Jackson-Patel

Contact details

Primary location

M&HS BUILDING 504 - Bldg 504
Level 0, Room 018
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand